Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York. Show more
Location: 345 Park Avenue South, New York, NY, 10010, United States | Website: https://www.protaratx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
124.6M
52 Wk Range
$1.59 - $10.48
Previous Close
$3.23
Open
$3.25
Volume
140,133
Day Range
$3.15 - $3.29
Enterprise Value
6.737M
Cash
122.2M
Avg Qtr Burn
-11.18M
Insider Ownership
2.79%
Institutional Own.
78.73%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IV Choline chloride Details Intestinal failure associated liver disease, Long-term parenteral support | Phase 3 Initiation | |
TARA-002 Details Non-muscle invasive bladder cancer | Phase 2 Data readout | |
TARA-002 Details Lymphatic malformations (LMs) | Phase 2 Data readout |